SubHero Banner

Polivy (polatuzumab vedotin-piiq) – New orphan drug approval

June 10, 2019 - The FDA announced the approval of Genentech’s Polivy (polatuzumab vedotin-piiq), in combination with bendamustine and a rituximab product (eg, Rituxan®), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.

Download PDF